Related Experiment Video
Updated: Nov 7, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Adjunctive Use of Statins for COVID-19
Mike Sathekge1,2, Geert Byttebier3, Bart De Spiegeleer4
1Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, 0002 Pretoria, South Africa.
Obesity and cardiometabolic disorders create a syndemic with COVID-19, necessitating social interventions and multiple drug treatments. This interaction highlights the need for integrated health strategies to combat severe outcomes.
Area of Science:
- Public Health
- Infectious Diseases
- Metabolic Disorders
Background:
- The COVID-19 pandemic has disproportionately affected individuals with obesity and cardiometabolic disorders.
- These pre-existing conditions exacerbate disease severity and mortality rates associated with SARS-CoV-2 infection.
Discussion:
- The convergence of obesity, cardiometabolic disorders, and COVID-19 forms a syndemic, amplifying health crises.
- Addressing this syndemic requires a dual approach: societal interventions and comprehensive pharmacological strategies.
Key Insights:
- Obesity and cardiometabolic conditions significantly increase the risk of severe COVID-19 outcomes.
- A multipharmacological approach is crucial for managing patients at the intersection of these health issues.
Outlook:
- Future research should focus on integrated strategies for prevention and treatment.
- Developing targeted public health policies and therapeutic guidelines is essential to mitigate the syndemic's impact.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Coronary Artery Disease V: Interprofessional Care
